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Human Vγ9Vδ2 T cells recognise pyrophosphate-based antigens (phosphoantigens) and have multiple functions in innate and
adaptive immunity, including a unique ability to activate other cells of the immune system. We used ﬂow cytometry and ELISA to
deﬁne the early cytokine proﬁles of Vγ9Vδ2 T cells stimulated in vitro with isopentenyl pyrophosphate (IPP) and (E)-4-hydroxy-
3-methyl-but-2 enyl pyrophosphate (HMB-PP) in the absence and presence of IL-2 and IL-15. We show that fresh Vγ9Vδ2Tc e l l s
produce interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α) within 4 hours of stimulation with phosphoantigen, but
neither IL-10, IL-13, nor IL-17 was detectable up to 72 hours under these conditions. Cytokine production was not inﬂuenced
by expression or lack, thereof, of CD4 or CD8. Addition of IL-2 or IL-15 caused expansion of IFN-γ-producing Vγ9Vδ2Tc e l l s ,
but did not enhance IFN-γ secretion after 24–72 hours. Thus, phosphoantigen-stimulated Vγ9Vδ2 T cells have potential as Th1-
biasing adjuvants for immunotherapy.
1.Introduction
γδ T cells constitute approximately 1–5% of circulating
human T lymphocytes, and the majority (typically >80%)
of these express T-cell receptors (TCRs) consisting of Vγ9
andVδ2chains.TheVγ2Vδ2TCRrecognisessmall,nonpep-
tide phosphate antigens (phosphoantigens) independently
of major histocompatibility complex (MHC) molecules
(reviewed in references [1, 2]). This γδ T-cell subset exists
only in humans and higher primates, where numerous roles
in immunosurveillance and protection against infection and
tumours have been hypothesised, yet a speciﬁc, unique
role remains to be found. In vitro studies have shown
that activated Vγ9Vδ2 T cells rapidly produce an array of
proinﬂammatory cytokines and chemokines [3], cytolytic
compounds [4, 5], antiviral [6], antimicrobial [7], and tissue
growth factors [8, 9]. Activating crosstalk has been described
between Vγ9Vδ2 T cells and other immune cells, such as
neutrophils [10], B cells [11], monocytes [12], and dendritic
cells [13–16]. The Vγ9Vδ2 T-cell subset has also been
shown to have antigen presentation and cross-presentation
capabilities comparable to those of professional antigen pre-
senting cells [17, 18]. The basis for this apparent functional
pleiotropy is unknown but is likely to be inﬂuenced by the
conditions under which γδ Tc e l l sb e c o m ea c t i v a t e d ,s u c h
as in the absence or presence of an ongoing inﬂammatory
response.
TheimperativetoreliablydeﬁneVγ9Vδ2Tcellresponses
is now more urgent, since these cells and their activating
antigens are currently of interest as immunotherapeutic
agents, particularly for treatment of cancer. In addition
to their antigen presenting [17, 18] and adjuvant [11–16]
activities, Vγ9Vδ2 T cells recognise and kill a range of
tumour cells in vitro [5, 19–21], and clinical trials in cancer
patients are ongoing [22–26]. Current treatment strategies
aim to optimally expand and activate Vγ9Vδ2 T cells (either
ex vivo or in vivo) by administering phosphoantigens along
with T-cell growth factors, most commonly IL-2, or by using2 Mediators of Inﬂammation
aminobisphosphonates which inhibit isoprenoid synthesis
resulting in the accumulation of endogenous phosphoanti-
gens [27]. Such strategies have shown evidence of improved
patient survival; however, the observed plasticity of Vγ9Vδ2
T cell functions presents a double-edged sword, with the
potential to treat disease balanced against the possibility of
triggeringundesirableimmuneresponses,orcellexhaustion.
Thus, further characterisation of activated Vγ9Vδ2Tc e l l s
is required if such cells are to be used to generate reliable
immunological outcomes.
Numerous studies have demonstrated that murine γδ
T-cell subsets can produce cytokines that control distinct
adaptive immune responses, such as those categorised as
T helper type 1 (Th1), Th2, Th17, or regulatory T (Treg)
responses [28–32]. Human Vγ9Vδ2 T cells can readily
release the Th1 cytokines IFN-γ and TNF-α [12, 14, 33–
37], and subsets of these cells can be induced under certain
conditions to produce Th2 (IL-4, IL-5 and IL-13), Th17
(IL-17), and Treg (IL-10) cytokines [11, 35, 38, 39]. In the
present study, we have characterised the early Th cytokine
proﬁles of primary Vγ9Vδ2 T cells taken from the peripheral
blood of healthy volunteers and stimulated in vitro with
phosphoantigens in the presence and absence of T-cell
growth factors IL-2 or IL-15. The antigens used were isopen-
tenyl pyrophosphate (IPP) and (E)-4-hydroxy-3-methyl-
but-2 enyl pyrophosphate (HMB-PP), intermediates of the
mevalonate and nonmevalonate pathways of isoprenoid
synthesis, respectively [40, 41]. HMB-PP is the most potent
γδ T cell stimulating antigen described to date [40] but has
yet to be clinically exploited. Our results show that Vγ9Vδ2
T cells stimulated with this novel phosphoantigen under
clinically relevant conditions have similar cytokine proﬁles
to IPP-stimulated Vγ9Vδ2 T cells, with rapid production
of cytokines that promote Th1 responses, but little or no
cytokines associated with Th2, Th17, or Treg responses.
2.MaterialsandMethods
2.1. Blood Samples and Preparation. Anticoagulated venous
blood samples were obtained from healthy donors. For γδ T-
cell enrichments, blood from buﬀy coat packs from the Irish
Blood Transfusion Service Board was used. Peripheral blood
mononuclear cells (PBMCs) were prepared by standard den-
sity gradient centrifugation over Lymphoprep (Nycomed,
Oslo, Norway).
2.2. Magnetic Bead Enrichment of αβ and γδ TC e l l s .γδ
T cells were enriched from PBMC by positive selection
using the Anti-TCR γδ Microbead Kit (Miltenyi Biotec,
BergischGladbach,Germany).TcellsnegativefortheγδTCR
(hereafter denoted αβ T cells) were prepared by positive
selection of CD3+ cells from the γδ TCR-negative fractions
using CD3 Microbeads (Miltenyi Biotec). Purity of αβ and
γδ T-cell fractions was assessed by ﬂow cytometry.
2.3. In Vitro Stimulation of T Cells. PBMC or enriched αβ
and γδ T cells were plated at 106 cells/mL in complete RPMI
medium (RPMI 1640 containing Glutamax supplemented
with25mMHEPES,50mg/mLstreptomycin,50U/mLpeni-
cillin, 2μg/mL Fungizone, and 10% heat-inactivated foetal
calf serum) and stimulated for 4–72 hours with phorbol
myristate acetate (PMA; 10ng/mL; Sigma-Aldrich, Poole,
UK) and ionomycin (1μg/mL; Sigma-Aldrich) or various
concentrations of the phosphoantigens IPP (0–100μM;
Sigma-Aldrich) or HMB-PP (0-1μM; kindly donated by
Hassan Jomaa and Armin Reichenberg) [42], with and with-
out IL-2 (50U/mL; donated by National Cancer Institute—
FrederickResearchFoundationBiologicalResourcesBranch)
or IL-15 (10ng/mL; R&D Systems, Abingdon, UK).
2.4.IntracellularAnalysisofCytokineProductionbyVγ9Vδ2T
Cells. Total PBMCs were stimulated for 4 hours as described
in Section 2.3 in the presence of brefeldin A (10μg/mL,
Sigma-Aldrich) to promote intracellular accumulation of
cytokines. Cells were harvested and stained for cell surface
expression of Vγ9, CD3, CD4, and/or CD8 and intracellular
expression of IFN-γ,T N F - α, IL-10, IL-13, or IL-17 using
ﬂuorochrome-conjugated monoclonal antibodies (mAb)
obtained from BD Biosciences, (Oxford, UK), Immunotools
(Friesoythe, Germany), eBioscience (Hatﬁeld, UK), and
R&D Systems (Abingdon, UK) [43]. Cells were analysed
using a FACSCalibur ﬂow cytometer withCellQuestsoftware
(BD Biosciences) or with a CyAN-ADP ﬂow cytometer
with Summit (Beckman Coulter) and FloJo (Ashland, OR)
software. Unstimulated control samples were incubated
alongside test samples and isotype-matched, nonspeciﬁc
mAbs, and ﬂuorescence-minus-one controls were used to set
compensations and gates.
2.5. Cytokine Quantiﬁcation by ELISA. αβ and γδ Tc e l l s
were enriched from PBMC by magnetic bead selection as
described in Section 2.2 and 0.2 × 106 cells per well of a 96-
well plate were stimulated in vitro as described in Section 2.3.
Supernatants from these cultures were harvested 24, 48, and
72 hours after stimulation and the levels of IFN-γ, IL-10, IL-
13, and IL-17 were quantiﬁed by ELISA using antibody pairs
purchased from R&D Systems (DuoSet ELISA Development
kits).
2.6. Statistical Analyses. Statistical analysis of data was
carried out using Prism GraphPad Version 5.0. Diﬀerences
between groups were assessed using paired t-test, and P
values of <.05 were considered signiﬁcant.
3. Results
3.1. Vγ9Vδ2 T Cells Rapidly Produce IFN-γ, But Not IL-10,
IL-13, Nor IL-17, in Response to Pyrophosphate Stimulation.
Early cytokine production by Vγ9Vδ2 T cells was examined
by stimulating freshly isolated PBMC for 4 hours with
medium alone, PMA and ionomycin, or various concen-
trations of IPP or HMB-PP in the presence of brefeldin
A( 1 0μg/mL). Cells were then washed and stained for cell
surface expression of CD3 and Vγ9o rV δ2 and intracellular
expression of IFN-γ, IL-10, IL-13, or IL-17. Virtually all
Vγ9+ cells expressed the Vδ2 chain and vice versa, withMediators of Inﬂammation 3
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Figure 1: Vγ9Vδ2 T cells rapidly produce IFN-γ, but not IL-10, IL-13, nor IL-17, in response to PMA and ionomycin or pyrophosphate
stimulation. (a) Flow cytometry dot plots showing IFN-γ, IL-10, IL-13, and IL-17 expression by Vγ9+ and Vγ9− PBMC after 4-hour
stimulation with PMA and ionomycin or HMB-PP, in the presence of brefeldin A. Plots are representative of experiments on PBMC from
8 donors. Numbers in the lower right hand quadrants indicate the percentages of lymphocytes that express the Vγ9 TCR. Numbers in the
upper right hand quadrants indicate the percentages of Vγ9+ T cells that produce each cytokine.4 Mediators of Inﬂammation
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Figure 2: IL-2 and IL-15 augment IFN-γ expression by phosphoantigen-stimulated Vγ9Vδ2 T cells. (a) Representative dot plots showing
IFN-γ expression by Vγ9 cells 4 hours after stimulation with IPP (10μM) or HMB-PP (10nM), in the absence or presence of 50U/mL IL-2
or 10ng/mL IL-15. Plots are representative of 8 independent studies. Numbers in the plots indicate the percentages of Vγ9− (left) and Vγ9+
(right) T cells that produce each cytokine. (b) Mean (± SEM) percentages (n = 8) of Vγ9 cells expressing IFN-γ after stimulation with
various concentrations of IPP or HMB-PP, in the absence and presence of IL-2 and IL-15.
single-positive Vγ9+ or Vδ2+ being very rare [16]; therefore,
Vγ9Vδ2 T cells were subsequently identiﬁed by a single
Vγ9 mAb stain. We found that the numbers of Vγ9+ cells
detectable by ﬂow cytometry after stimulation of PBMC
with PMA and ionomycin were usually lower than those
detectableinunstimulatedPBMCfromthesamedonors(not
shown) or after stimulation with phosphoantigen (Figure 1).
This may be due to proliferation of other non-Vγ9+ cells orMediators of Inﬂammation 5
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Figure 3: IFN-γ production in response to HMB-PP is restricted to γδ T cells and is highest 72 hours after simulation. Freshly isolated
PBMCs were enriched for αβ and γδ T cells using magnetic beads, and 200,000 cells of each population were stimulated with various
concentrations of HMB-PP (a and c) or IPP (b). The levels of IFN-γ in cell supernatants were quantiﬁed by ELISA after 24 hours (a and b)
or 72 hours (c). Results are expressed as mean (± SEM) levels of IFN-γ released by αβ and γδ T cells from 2–8 donors. (d) Mean (± SEM)
IFN-γ production by γδ T cells from 8 donors after stimulation with 10μM IPP, 10nM HMB-PP, 50U/mL IL-2, and/or 10ng/mL IL-15 as
indicated. ∗P<. 05 compared to unstimulated cells (medium). ns: not signiﬁcant comparing absence and presence of IL-2 and IL-15.
downregulation of TCR expression by Vγ9Vδ2 T cells, which
occurs after stimulation with PMA and ionomycin but not
HMB-PP [44].
Analysis of early cytokine production by fresh PBMC
from 8 healthy donors showed that Vγ9 cells produced
IFN-γ, but not IL-10, IL-13, nor IL-17 within 4 hours
of stimulation with either IPP (data not shown), HMB-
PP (Figure 1), or PMA and ionomycin (Figure 1). The
percentages of Vγ9+ cells that produced IFN-γ did not
increase with greater stimulation times (data not shown).
Cytokine production by non-Vγ9Vδ2 cells never exceeded
backgroundlevels(0.4%)inresponsetophosphoantigensyet
was evident in response to PMA and ionomycin treatment,
for all cytokines assayed (Figure 1).
3.2. IL-2 and IL-15 Augment IFN-γ Expression But Do Not
Induce IL-10, IL-13, Nor IL-17 Expression by Phosphoantigen-
Stimulated Vγ9Vδ2TC e l l s .The frequencies of Vγ9Vδ2T6 Mediators of Inﬂammation
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Figure 4: Phosphoantigen stimulation of γδ T cells causes no detectable increase in IL-10, IL-13, or IL-17 production. Freshly isolated
PBMCs were enriched for γδ T cells using magnetic beads, and 200,000 cells were stimulated with 10μMI P P ,1 0n MH M B - P P ,5 0U / m L
IL-2, and/or 10ng/mL IL-15 as indicated. The levels of IL-10 (a), IL-13 (b), and IL-17 (c) in cell supernatants were measured by ELISA after
72 hours. Bar charts show mean cytokine levels for all treatments for 8 donors. ns: not signiﬁcant comparing absence and presence of IL-2
and IL-15. PMA/I-PBMC, cytokine levels released by PMA and ionomycin-stimulated PBMC.
cells that produced IFN-γ in response to stimulation of
PBMC with IPP or HMB-PP were enhanced by adding
IL-2 or IL-15 to culture media (Figure 2(a)). Addition
of these growth factors did not lead to the induction of
IL-10, IL-13, nor IL-17 production by phosphoantigen-
stimulated Vγ9Vδ2+ or Vγ9Vδ2− T cells (not shown). The
percentages of Vγ9Vδ2 T cells producing IFN-γ increased
in a dose-dependent manner in response to IPP and HMB-
PP, with half-maximal stimulation occurring when 10μM
IPP or 1nM HMB-PP were used (Figure 2(b)). Therefore,
as previously reported [40, 41], HMB-PP was ∼10,000-fold
more potent than IPP at stimulating IFN-γ production by
Vγ9Vδ2 cells. While the presence of IL-2 or IL-15 in cell
stimulations led to increases in the percentages of Vγ9Vδ2
T cells that produced IFN-γ, it did not signiﬁcantly lower
the concentrations of phosphoantigens that were required to
induce IFN-γ expression (Figure 2(b)).
3.3. γδ T Cells Release Maximal Amounts of IFN-γ 72 Hours
afterPhosphoantigenStimulation. Wealsomeasuredlevelsof
IFN-γ,IL-10,IL-13,andIL-17thatwerereleasedintoculture
supernatants of pyrophosphate-stimulated γδ TCR+ and γδ
TCR
− (denoted αβ) T cells using ELISA. αβ and γδ Tc e l l s
were enriched using magnetic beads, and 0.2 × 106 cells of
each type were stimulated with various concentrations of
HMB-PP or IPP in the absence or presence of IL-2 or IL-
15. After 24 hours, IFN-γ was detectable in the supernatants
of Vγ9Vδ2 T cells, with half-maximal levels seen when
20μMI P Po r1n MH M B - P Pw e r eu s e d( F i g u r e s3(a) and
3(b)). In contrast, very low levels of IFN-γ were released by
phosphoantigen-exposed αβ T cells. Measurement of IFN-
γ levels 24, 48, and 72 hours after stimulation indicated
that maximal amounts were detectable after 72 hours, with
levels 5–10 times higher than observed after 24 hours
(Figure 3(c)).Mediators of Inﬂammation 7
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Figure 3(d) shows that stimulation of Vγ9Vδ2Tc e l l s
with IPP or HMB-PP for 72 hours resulted in signiﬁcant
IFN-γ release. We found that after culturing unstimulated
Vγ9Vδ2 T cells for 72 hours in the presence of IL-2 or IL-
15, low levels (means 0.9 and 1.2ng/mL, resp.) of IFN-γ
were detectable in the culture supernatants. However, IL-
2 or IL-15 only slightly augmented the amounts of IFN-
γ released by phosphoantigen-stimulated Vγ9Vδ2Tc e l l s
in 3 experiments. Thus, although IL-2 and IL-15 increase
the frequencies of pyrophosphate-stimulated Vγ9Vδ2Tc e l l s
that express IFN-γ at an early time point (Figure 2), they do
not signiﬁcantly enhance the overall levels of IFN-γ released
by these cells after 72 hours.
3.4. γδ T Cells Do Not Secrete IL-10, IL-13, Nor IL-
17 in Response to Phosphoantigen Stimulation But Can
Release IL-13 in Response to Treatment with IL-2 or IL-15.
While enriched γδ T cells signiﬁcantly upregulated IFN-
γ in response to pyrophosphate stimulation (Figure 3), no
upregulation of IL-10, IL-13, nor IL-17 was detected at any
time point after stimulation (Figure 4). We observed that,
in contrast to IFN-γ, even PMA and ionomycin treatment
was insuﬃcient to upregulate IL-10 nor IL-17 production
by γδ T cells, even though these cytokines were released by
PMA and ionomycin-treated total PBMC. Addition of IL-
2 or IL-15 to unstimulated, IPP-stimulated, or HMB-PP-
stimulated γδ T cells resulted in low level secretion of IL-
13 (but not IL-10 nor IL-17) after 72 hours (Figure 4(b)).
Therefore, while pyrophosphate stimulation did not induce
IL-13 release by γδ T cells, some γδ T cells are nevertheless
capable of producing this cytokine when cultured with the
g r o w t hf a c t o r sI L - 2o rI L - 1 5 .
3.5. Cytokine Production by Vγ9Vδ2TC e l l sI sI n d e p e n d e n t
of CD4 or CD8 Expression. Cytokine production by αβ
T cells can vary according to whether they express CD4,
CD8, or neither. We used ﬂow cytometry to examine CD4
and CD8 expression by Vγ9Vδ2 T cells and found that
>75% were negative for these coreceptors in 4 of 6 donors.
However signiﬁcant numbers of CD4+,C D 8 +, and double-
negative Vγ9Vδ2Tc e l l sw e r ef o u n di na l ls u b j e c t s( F i g u r e s
5(a)–5(c)). We next investigated whether these subsets of
Vγ9Vδ2Tc e l l sc a np r o d u c eT N F - α or IFN-γ. Electronic
gating on Vγ9Vδ2 T cells from 6 donors revealed that over
25% of CD4+ and CD8+ Vγ9Vδ2 T cells expressed TNF-
α (Figures 5(d), 5(e), and 5(g)) and IFN-γ (Figure 5(h))
upon PMA and ionomycin stimulation. Electronic gating on
CD4−CD8− Vγ9Vδ2 T cells indicated that >35% of PMA
and ionomycin-stimulated cells within this double-negative
subset also produced these cytokines (Figures 5(f), 5(g), and
5(h)). Thus, cytokine production by Vγ9Vδ2 cells does not
appear to correlate with CD4 or CD8 expression as for αβ
T cells, with signiﬁcant proportions of CD4+,C D 8 +,a n d
double-negative Vγ9Vδ2 T cells capable of producing Th1
cytokines.
4. Discussion
Vγ9Vδ2 T cells are innate lymphocytes that are thought to
play key roles in immune sensing of danger and initiation
and regulation of innate and adaptive immunity. They
respond to a variety of signals including ligands for toll-
like receptors [45, 46], stress-inducible ligands on infected
and tumour cells [47], and phosphoantigens which may be
produced endogenously or by microorganisms [1, 48]. They
respond with a plethora of immunostimulatory functions,
including cytotoxicity [5, 19–21], direct activation of other
cells of the immune system [11–18], and indirect control of
immuneresponsesviatherapidsecretionofchemokinesand
cytokines [3, 6, 7, 10, 11]. For these reasons, Vγ9Vδ2Tc e l l s
have attracted considerable interest as therapeutic agents for
infectiousandimmune-mediateddiseaseandcancer.Indeed,
Vγ9Vδ2 T cells may perhaps be more rational candidates
as immunotherapeutic targets than invariant natural killer
T (iNKT) cells, which also recognise nonpeptide antigens
via a conserved TCR and mediate antitumour immunity but
are found at ∼100-fold lower frequencies in human blood
compared to Vγ9Vδ2Tc e l l s[ 49].
Clinical trials using various Vγ9Vδ2 T cell activating
agents, such as aminobisphosphonates and phosphoanti-
gens, are ongoing for treatment of cancer [22–26]. Such
trials report low toxicity and improved objective clinical
outcomesincludingstabilisationandpartialorfullremission
of advanced-stage metastatic carcinomas of the prostate,
lung, and kidney. Therapeutic activation of Vγ9Vδ2Tc e l l s
may also prove to be beneﬁcial in numerous other disease
settings, due to their potent adjuvant and eﬀector functions
in innate and adaptive immunity [10–16]. However, it is
conceivable that the same potent activities could lead to the
activationofundesirableimmuneresponsesthatcouldresult
in inﬂammatory or autoimmune disease; therefore, further
characterisation of the mechanisms by which Vγ9Vδ2Tc e l l s
respond to diﬀerent stimuli is required.
In this study, we analysed the cytokine production
proﬁles of Vγ9Vδ2Tc e l l st r e a t e din vitro in a similar
manner to current immunotherapeutic protocols, that is,
using phosphoantigens and T-cell growth factors. We used
two phosphoantigens, the prototype IPP [48] and the more
potent HMB-PP, which can induce proliferation, cytotox-
icity, and cytokine secretion by Vγ9Vδ2Tc e l l se v e na t
subnanomolar concentrations [40, 41]. These antigens were
used to stimulate freshly isolated Vγ9Vδ2Tc e l l sin vitro,i n
the presence and absence of IL-2 and IL-15, and the early
production of cytokines that help polarise adaptive immune
responses was examined.
Our results show that Vγ9Vδ2 T cells promptly pro-
duce the proinﬂammatory cytokines IFN-γ and TNF-α,
in response to phosphoantigen stimulation, with IFN-γ-
producing cells detected as early as 4 hours after stimulation.
In contrast, we were unable to detect any upregulation of
IL-10, IL-13, or IL-17 production in response to phospho-
antigen stimulation. This Th1 cytokine proﬁle was observed
exclusively in Vγ9Vδ2 T cells when freshly isolated PBMCs
were stimulated with either IPP or HMB-PP, and intracel-
lular cytokine expression was analysed by ﬂow cytometry.
The same proﬁle was seen when magnetic bead-enriched
γδ T cells were stimulated for up to 72 hours and released
cytokine was quantiﬁed by ELISA. The frequencies of IFN-γ
expressing Vγ9Vδ2 T cells and amounts of cytokine releasedMediators of Inﬂammation 9
followed dose-dependent responses to each pyrophosphate,
with HMB-PP being ∼10,000-fold more potent than IPP, in
agreement with previous reports [41, 42].
The addition of IL-2 or IL-15 to pyrophosphate stimula-
tionsledtomoderateincreasesintheproportionsofVγ9Vδ2
T cells that produced IFN-γ within 4 hours of stimulation,
but these increases only translated into a slight enhancement
in IFN-γ levels, when supernatants were analysed after 72
hours. This suggests that IL-2 and IL-15 speed up the
kinetics of the Vγ9Vδ2 response, without synergising with
phosphoantigens in inducing IFN-γ production, perhaps
by stimulating cell division and proliferation of IFN-γ-
expressing Vγ9Vδ2 T cells rather than directly stimulating
IFN-γ secretion. This result may also be explained by the
presence of other accessory cells, such as antigen-presenting
cells [50], within the PBMC used for intracellular cytokine
detection, which were absent from the enriched γδ T-cell
preparations used for ELISA.
Interestingly, γδ T cells incubated with IL-2 or IL-
15 in the absence of phosphoantigen stimulation released
moderate amounts of IFN-γ and IL-13, but not IL-10 nor IL-
17. This IFN-γ production was augmented by simultaneous
stimulation with HMB-PP or IPP, but the IL-13 production
was not. This suggests that phosphoantigen stimulation of
Vγ9Vδ2 T cells results in secretion of IFN-γ but not IL-13,
while treatment with IL-2 or IL-15 can induce secretion of
both cytokines. Alternatively, the IFN-γ and IL-13 released
in response to IL-2 or IL-15 may emanate from non-Vγ9Vδ2
T cells present in the enriched γδ T-cell preparations, such
as Vδ1+ T cells. However, our results clearly show that
Vγ9Vδ2 T cells release IFN-γ a n dn o tI L - 1 3i nr e s p o n s et o
phosphoantigen stimulation.
Following conﬁrmation that phosphoantigen-stimulated
Vγ9Vδ2 T cells produce IFN-γ and TNF-α,w en e x ti n v e s -
tigated whether this cytokine proﬁle is restricted to CD4+,
CD8+,o rd o u b l e - n e g a t i v eV γ9Vδ2 T cells. We found that
all 3 subtypes of Vγ9Vδ2 T cells were found in all 6 donors
tested, with double negative cells predominating. Signiﬁcant
proportions of all 3 Vγ9Vδ2 T cell subsets produced IFN-
γ and TNF-α upon stimulation, showing CD4 or CD8
expression does not impact on cytokine production by these
cells.
The present ﬁndings are in agreement with previous
studies that have shown that phosphoantigen-stimulated
Vγ9Vδ2TcellsreleasecytokinesthatpromoteTh1responses
[12, 14, 33–37]. We also conﬁrm that IL-2 or IL-15 augment
Th1 cytokine production by these cells [36, 38]. We show,
for the ﬁrst time, that the CD4+,C D 8 +, and double-negative
Vγ9Vδ2 T cell subsets all exhibit this Th1 cytokine proﬁle.
O u rd a t aﬁ tw i t hp r e v i o u so b s e r v a t i o n sf r o mu sa n do t h e r s
that phosphoantigen-stimulated Vγ9Vδ2 T cells possess
Th1-promotingadjuvantactivityfordendriticcells,inducing
them to mature into antigen-presenting cells that release IL-
12 but not IL-10 [14, 16], although Eberl and coworkers
[12] reported that Vγ9Vδ2 T cells can induce maturation
of monocytes into antigen-presenting cells that stimulated
Th1 and Th17 cells. Although Vγ9Vδ2Tc e l l sa p p e a rt ob e
Th1 inducers, other studies have shown that subsets of these
cells can release other Th cell-polarising cytokines under
diﬀerent conditions. Wesch and co-workers [35]r e p o r t e d
that Vγ9Vδ2 T cells stimulated with IPP in the presence
of IL-12 and anti-IL-4 mAb (Th1-priming conditions)
produced IFN-γ and TNF-α, but when stimulated in the
presence of IL-4 and anti-12 mAb (Th2 priming) they
produced IL-4. Vermijlen and co-workers [38] reported that
Vγ9Vδ2 T cells stimulated with HMB-PP and IL-2 can also
produce IL-5 and IL-13, but in agreement with our results,
these authors also found that treatment of Vγ9Vδ2Tc e l l s
with IL-2 in the absence of phosphoantigen stimulation was
suﬃcient to induce IL-13 production [38]. A minor subset
of Vγ9Vδ2 T cells characterised by the expression of CXCR5
and CD27 has also been reported to release IL-4 and IL-
10 following stimulation with a synthetic phosphoantigen
[11]. IL-17 and IL-22 production by a minority (<0.1%) of
Vγ9Vδ2 T cells stimulated with HMB-PP in the presence
of IL-1β,T G F - β and IL-6, or IL-23 has also been reported
[39]. Thus, it is clear that some Vγ9Vδ2Tc e l l sc a nb e
induced to produce various cytokines, but whether they do
so under physiological conditions is unclear. Furthermore,
such cells appear to account for very small proportions of
peripheralbloodVγ9Vδ2Tcells,whichundertheconditions
used in the present study make very small contributions to
the overall cytokine proﬁle of phosphoantigen-stimulated
Vγ9Vδ2 T cells.
In conclusion, we have shown here that IPP and the
novel phosphoantigen HMB-PP rapidly activates a strong
proinﬂammatory response speciﬁc to Vγ9Vδ2Tc e l l sa n d
thus shows promise as an immunotherapeutic agent, worthy
of further evaluation. Furthermore, we conﬁrm that Vγ9Vδ2
T cells are also responsive to lymphocyte growth factors.
These responses seen with fresh, uncultured Vγ9Vδ2Tc e l l s
are similar to those seen with Vγ9Vδ2 T cells that were
expanded in vitro with HMB-PP and IL-2 [16]. Future
studies are required to ascertain the eﬀects of stimulating
Vγ9Vδ2 T cells through other non-TCR stimulatory recep-
tors, such as toll-like receptors [45, 46]a n dN K G 2 D[ 47]
and inhibitory receptors [51], and the eﬀects of ligating
various costimulatory and inhibitory receptors. Clariﬁcation
of these responses may allow selective induction of particular
Vγ9Vδ2 T-cell subsets or functions and thus greatly enhance
the gamut of immunotherapeutic tools available.
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